BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32388719)

  • 1. Expression and prognostic significance of pyruvate dehydrogenase kinase 1 in bladder urothelial carcinoma.
    Zhu J; Zheng G; Xu H; Jin X; Tang T; Wang X
    Virchows Arch; 2020 Nov; 477(5):637-649. PubMed ID: 32388719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serine threonine kinase 15 amplification in normal urothelium of cystectomy specimens is no prognostic factor in urothelial carcinoma of the bladder.
    Otto W; Fritsche HM; Wild PJ; Wieland WF; Hartmann A; Burger M; Hofstädter F; Denzinger S
    Pathol Res Pract; 2011 Mar; 207(3):161-3. PubMed ID: 21247708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and function analysis of indoleamine 2 and 3-dioxygenase in bladder urothelial carcinoma.
    Yang C; Zhou Y; Zhang L; Jin C; Li M; Ye L
    Int J Clin Exp Pathol; 2015; 8(2):1768-75. PubMed ID: 25973066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
    Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
    Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
    Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
    Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UBE2C is a marker of unfavorable prognosis in bladder cancer after radical cystectomy.
    Morikawa T; Kawai T; Abe H; Kume H; Homma Y; Fukayama M
    Int J Clin Exp Pathol; 2013; 6(7):1367-74. PubMed ID: 23826418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
    Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
    Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma.
    Bao Z; Zhang W; Dong D
    Oncotarget; 2017 Feb; 8(6):10485-10497. PubMed ID: 28060759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sphingosine-1-phosphate receptor 1 (S1PR1) expression in non-muscle invasive urothelial carcinoma: Association with poor clinical outcome and potential therapeutic target.
    Go H; Kim PJ; Jeon YK; Cho YM; Kim K; Park BH; Ku JY
    Eur J Cancer; 2015 Sep; 51(14):1937-45. PubMed ID: 26238015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival.
    Luo JH; Xie D; Liu MZ; Chen W; Liu YD; Wu GQ; Kung HF; Zeng YX; Guan XY
    Int J Cancer; 2008 Jun; 122(11):2554-61. PubMed ID: 18246597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer.
    Poyet C; Buser L; Roudnicky F; Detmar M; Hermanns T; Mannhard D; Höhn A; Rüschoff J; Zhong Q; Sulser T; Moch H; Wild PJ
    J Clin Pathol; 2015 Oct; 68(10):819-24. PubMed ID: 26251520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and function of SIRT6 in muscle invasive urothelial carcinoma of the bladder.
    Wu M; Dickinson SI; Wang X; Zhang J
    Int J Clin Exp Pathol; 2014; 7(10):6504-13. PubMed ID: 25400728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
    Chang WC; Chang YH; Pan CC
    Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion.
    Haghayeghi K; Lu S; Matoso A; Schiff SF; Mueller-Leonhard C; Amin A
    Virchows Arch; 2021 Sep; 479(3):515-521. PubMed ID: 34218288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer.
    Ottley EC; Pell R; Brazier B; Hollidge J; Kartsonaki C; Browning L; O'Neill E; Kiltie AE
    J Pathol Clin Res; 2020 Oct; 6(4):238-251. PubMed ID: 32374509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
    Davick JJ; Frierson HF; Smolkin M; Gru AA
    Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer.
    Margulis V; Lotan Y; Karakiewicz PI; Fradet Y; Ashfaq R; Capitanio U; Montorsi F; Bastian PJ; Nielsen ME; Müller SC; Rigaud J; Heukamp LC; Netto G; Lerner SP; Sagalowsky AI; Shariat SF
    J Natl Cancer Inst; 2009 Jan; 101(2):114-9. PubMed ID: 19141773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy.
    Liu A; Xue Y; Liu F; Tan H; Xiong Q; Zeng S; Zhang Z; Gao X; Sun Y; Xu C
    Cancer Biomark; 2019; 26(3):281-289. PubMed ID: 31594208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.